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tein from the vesicular stomatitis virus Indiana strain
(VSVind.G). However, lentivector producer cell lines that sta-
bly express VSVind.G have not been reported, presumably
because of its cytotoxicity, preventing simple scale-up of vector
production. Interestingly, we showed that VSVind.G and other
vesiculovirus G from the VSVNew Jersey strain (VSVnj), Cocal
virus (COCV), and Piry virus (PIRYV) could be constitutively
expressed and supported lentivector production for up to
10 weeks. All G-enveloped particles were robust, allowing con-
centration and freeze-thawing. COCV.G and PIRYV.G were
resistant to complement inactivation, and, using chimeras
between VSVind.G and COCV.G, the determinant for comple-
ment inactivation of VSVind.G was mapped to amino acid res-
idues 136–370. Clonal packaging cell lines using COCV.G
could be generated; however, during attempts to establish LV
producer cells, vector superinfection was observed following
the introduction of a lentivector genome. This could be pre-
vented by culturing the cells with the antiviral drug nevirapine.
As an alternative countermeasure, we demonstrated that
functional lentivectors could be reconstituted by admixing su-
pernatant from stable cells producing unenveloped virus with
supernatant containing envelopes harvested from cells stably
expressing VSVind.G, COCV.G, or PIRYV.G.Received 23 March 2018; accepted 30 July 2018;
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Progress in both gene therapy for inherited hematopoietic disorders
and also T cell therapy for cancer relies on the use of lentiviral vectors
(LVs).1 The LVs used so far in the clinic have been made via transient
transfection (usually of 293 or 293T cells) with plasmids encoding
HIV gag-pol, HIV rev, the viral vector, and the vesicular stomatitis vi-
rus Indiana strain (VSVind) envelope, a process similar to the labora-
tory method described 20 years ago.2,3 A similar transfection process
using the VSVind envelope has also been described for the production
of gammaretroviral vectors, where the robust nature of this G protein
confers vectors the ability to be concentrated to a high titer by ultra-
centrifugation4 and puriﬁed using chromatography processes.5Molecular Therapy: Me
This is an open access article under the CC BY-NC-A robust and readily scalable process for LV production is becoming
ever more necessary as clinical gene therapy becomesmore successful.
Because of reported problems with constitutive expression of the en-
velope G protein from VSVind (VSVind.G) on producer cells,4 LV
producer cell lines with inducible VSVind.G expression have been
constructed.6,7 However, these have not yet been employed for clin-
ical LV production. Another approach has used a non-toxic gammar-
etroviral envelope from the feline endogenous virus RD114 with a
modiﬁed cytoplasmic tail to allow LV incorporation.8–11 Although
a producer cell clone for clinical use has been developed, this has
not progressed to a clinical trial.12
The RD114 envelope is suited to the transduction of lymphocytes and
bone marrow stem cells.13,14 Also, when cells are transduced in vitro,
the RD114 LV can be captured by retronectin to purify and concen-
trate the vectors.15 However, LV particles with RD114-derived enve-
lopes are less infectious than those with VSVind.G in most cell lines
tested.8 Also, RD114-enveloped LVs tend to shed the envelope during
puriﬁcation, resulting in loss of vector titer.16 Therefore, it is of inter-
est to develop constitutive producer cell lines for LVs with the
VSVind.G envelope as an alternative to inducible systems. Constitu-
tive compared with inducible vector production would allow simpler
manufacturing process; e.g., no requirement for induction or suppres-
sion chemicals and potential continuous culture and harvest.We tried
to solve this problem by examining whether related vesiculovirus en-
velopes from the VSV New Jersey strain (VSVnj), Cocal virus
(COCV), and Piry virus (PIRYV) could be stably expressed. There
is limited information on receptor usage or the cellular infection
mechanism of vesiculovirus envelope G proteins other than VSVind.
It has been reported that, like VSVind.G, COCV.G has broad cell
tropism,17 whereas Chandipura virus G (CHAV.G) and PIRYV.Gthods & Clinical Development Vol. 10 September 2018 ª 2018 303
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Figure 1. Construction of VesG Envelope Expression
Plasmids
(A) G proteins of the major vesiculoviruses as well as the
G protein of the rabies virus (RABV) were analyzed with
regards to their phylogenetic relationship. The tree is drawn
to scale, with branch lengths measured in the number of
substitutions per site, depicted in the linear scale. VSVind,
vesicular stomatitis virus Indiana strain; COCV, Cocal virus;
VSVnj, vesicular stomatitis virus New Jersey strain; PIRYV,
Piry virus; CJSV, Carajas virus; ISFV, Isfahan virus; MARAV,
Maraba virus; VSVala, vesicular stomatitis virus Alagoas
strain. The vesiculoviruses we investigated are highlighted in
boxes, and information regarding their isolation and hosts is
summarized in the table on the right.46–48 (B) Vesiculovirus
G proteins were subcloned into the pMD2 plasmid back-
bone in which themarker gene, Sh ble, and the G protein are
linked by the FMDV 2A self-cleaving peptide and, therefore,
are controlled by a single CMV promoter.
Molecular Therapy: Methods & Clinical Developmentpseudotyped LVs are suboptimal in transducing non-adherent cells,
including lymphoid and hematopoietic stem cells.18 Recently, the
3D structure of the interaction between VSVind.G and its major re-
ceptor, low-density lipoprotein receptor (LDLR), has been eluci-
dated.19,20 However, the identiﬁed LDLR binding epitope is not
conserved among vesiculovirus G protein (VesG), and, therefore,
the use of this receptor cannot be generalized to the genus. In support
of this, CHAV.G does not interact with LDLR.19 Furthermore, it has
been postulated that all VesG go through similar structural and
conformational changes during pH-dependent fusion.21 However,
studies of wild-type virus infectivity and pre and post-fusion struc-
tures highlighted several differences regarding fusogenicity at acidic
pH levels22 and the nature of pH-sensitive switches.23
Here we looked at the cytotoxicity of the vesiculovirus envelopes,
including VSVind.G and whether they could be stably expressed and
sustain the construction of stable constitutive LV producer cell lines.RESULTS
Investigation of the Fusogenic Cytotoxicity of VesGs
To examine the cytotoxicity of vesiculovirus envelope glycoproteins
(G proteins), we constructed vectors with the Streptoalloteichus hin-
dustanus phleomycin inhibitor expressed as a fusion protein with
the G proteins, separated by a foot-and-mouth disease virus
(FMDV) 2A self-cleaving peptide24,25 (Figure 1). As a control enve-
lope, we used that from the feline endogenous gammaretrovirus
RD114 with a modiﬁed cytoplasmic tail (RDpro),8 which can be
readily expressed on stable packaging cells.8,10
We transfected 293T cells with each vector and then plated different
numbers of cells in the presence of phleomycin. Interestingly, we
found that each envelope yielded a similar number of phleomycin-
resistant colonies, with approximately one colony per 100 transfected
cells (Figure 2). This suggested that there is no difference in toxicity
between the various VesGs and the RDpro envelope.304 Molecular Therapy: Methods & Clinical Development Vol. 10 SepteEstablishment of Stable Envelope-Expressing Cells and Long-
Term Vector Production
To conﬁrm that the VesGs were indeed expressed on the transfected
cells, we cultured bulk-selected populations for up to 10 weeks and
detected envelope expression using the antiserum VSV-Poly, which
has been reported to recognize VSVind.G.26 This antibody detected
all VesGs on transiently transfected cells (Figure 3A, left); COCV.G
was detected with intermediate efﬁciency, and VSVnj.G and
PIRYV.G were weakly detected. After 10 weeks in culture, each
bulk-selected population still expressed the respective G proteins,
although, in each case, a proportion of the bulk-transfected and
-selected, cells showed a lower level of expression than the transiently
transfected population (Figure 3A, right). These bulk-selected popu-
lations expressing G proteins could produce LVs after transient sup-
ply of gag-pol, rev, and vector expression plasmids with titers of over
106 transduction units (TUs)/mL obtained with VSVind.G and
COCV.G, with approximately 5  105 TUs/mL for VSVnj.G and
PIRYV.G 4 weeks after selection, the earliest time when sufﬁcient cells
could be obtained (Figure 3B). Over the course of 10 weeks, a steady
drop in VesG expression and functional LV titers was observed.
COCV.G and VSVind.G were able to retain relatively high titers
compared with VSVnj.G and PIRYV.G, making them promising can-
didates as packaging cell line (PCL) envelopes. The titers in each case
tended to decrease after longer selection, perhaps because of the
enrichment of low G protein-expressing cells in the bulk populations
noted in Figure 3A.
To establish which VesGs are most promising to generate a stable
packaging cell line, their physical stability was tested using transiently
produced LV. Figure 4A shows that LVs with all vesiculovirus enve-
lopes were readily concentrated by centrifugation, as has been re-
ported for VSVind.G.16 In addition, they were all stable during
freeze-thawing and, in general, stable during incubation at 4C or
37C. VSVind.G, COCV.G, VSVnj.G, and PIRYV.G were stable after
three cycles of freeze-thawing and incubation at 37C, with a mini-
mum recovery percentage of 80%. PIRYV.G was less stable duringmber 2018
Figure 2. Colony Formation in the Presence of the
Selection Marker Reveals No Difference in Toxicity of
the G Proteins
To compare the cytotoxicity in various VesGs, HEK293T
cells were transfected with pMD2-2A-VSVind.G, pMD2-
2A-COCV.G, pMD2-2A-VSVnj.G, pMD2-2A-PIRYV.G, and
pRDpro-LF.8 48 hr post-transfection, cells were seeded in
different dilutions (the seeding density is indicated), selected
with phleomycin for 1 week, and then fixed and stained with
Giemsa. Similar numbers of colonies were formed for each
construct, suggesting that all of these G proteins have
similar levels of cytotoxicity. The data shown represent one
of the two different repeats performed.
www.moleculartherapy.orgincubation at 4C, as was the RDpro envelope used as a control
(Figure 4B).
COCV.G and PIRYV.G Are More Resistant to Complement-
Mediated Inactivation by Mammalian Sera
VSVind.G is known to be inactivated by complement,27–31 making it
less suitable for in vivo gene therapy application, where exposure to
the bloodstream will occur. When we tested LVs with other vesiculo-
virus envelopes, we found that VSVnj.G was also inactivated by hu-
man, mouse, guinea pig, and rabbit complement, whereas COCV.G
and PIRYV.G were resistant, as was the control RDpro, as reported
previously32,33 (Figure 5A). This differential sensitivity allowed us
to map the region of the envelope responsible by constructing chi-
meras between VSVind.G and COCV.G; these were designed so
that the protein junctions were made in regions of homology between
the two G proteins (Figure 5B). These chimeras were expressed as de-
tected by ﬂow cytometric analysis of 8G5F11 (Kerafast, Boston, MA)
immunostaining, an extracellular anti-VSVind.G mAb, and could
produce infectious LVs at levels comparable with VSVind.G following
transient transfection).34 LVs expressing the chimeric G proteins 4A,
1B, and 2B were resistant to human serum inactivation, suggesting
that the region of VSVind.G between amino acids 136 and 370 con-
fers complement sensitivity (Figure 5C). On the crystal structure
of VSVind.G, this region corresponds to most of the pleckstrin ho-
mology domain and parts of the fusion, trimerization, and lateral
domains (Figure S1).35,36
WinPac-COCV.G Packaging Cell Line: Establishment and
Identification of Superinfection
These experiments indicated that COCV.G was a suitable envelope
for lentivirus manufacture and in vivo use because it was thermostable
and complement-resistant. We therefore transfected WinPac cells,10
which stably express HIV gag-pol and rev, with a COCV.G expression
vector (Figure S2A) and isolated single-cell clones by selection in
phleomycin. Functional clones were identiﬁed by transient transfec-Molecular Therapy: Methods & Clintion of a lentivector construct containing the gfp
gene; data from 13 of these clones are shown in
Figure S2B. Clone H4 was shown to generate
LV titers of approximately 106 TUs/mL, only
2–3 times lower than that obtained by transienttransfection of all components (Figure 4). COCV.G expression on
clone H4 was maintained after long-term culture for 40 passages
(3 months) (Figure S2C), albeit at lower levels compared with tran-
sient expression.
The ﬁnal step in the construction of a producer cell line was to intro-
duce a stable vector construct into the WinPac-COCV.G H4 clone.
To do this, we employed a construct with a promoterless blasticidin
resistance gene (BSR), pSIN-GFP-BSR, which confers BSR expression
following integration next to a cellular promoter (Figure 6A). Trans-
fection of WinPac-COCV.G cells with this construct yielded a poly-
clonal population that could be expanded to harvest LVs. LV yields
from the WinPac-COCV.G bulk population and WinPac-RDpro sta-
ble producer cell clones were compared by seeding cells in Corning
HYPERFlask and harvesting LVs each day for 5 days (Figure 6B).
The stable WinPac-RDpro producer cell clone generated more LVs
under these conditions than the WinPac-COCV.G H4 bulk popula-
tion, in contrast to the relative titers following transient transfection,
where COCV.G was higher (Figure 4).
When we examined cells after long-term culture for 10 weeks, the cell
pellet of WinPac-COCV.G (H4) became visibly greener, whereas no
changes were observed for WinPac-RDpro cells (Figure S3). Previous
reports have described that cells expressing VSVind.G were not
blocked for superinfection by VSVind.37 In contrast, expression of
gammaretrovirus (GRV) envelopes blocks superinfection by viruses
that use the same receptor.38 An infection assay demonstrated that
WinPac-RDpro cells blocked RDpro-pseudotyped LV infection,
whereas WinPac-COCV.G cells were permissive to infection by
COCV.G-LV (Figure 7A). Furthermore, cells stably expressing each
of the VesGs could be readily infected with LVs pseudotyped with
VesG envelopes, whereas a superinfection block of RDpro-enveloped
LVs was observed in RDpro envelope-expressing cells (Figure 7B).
We therefore hypothesized that stable WinPac-COCV.G producer
cells become superinfected with LV genomes when cultured forical Development Vol. 10 September 2018 305
Figure 3. Development of Stable Envelope-
Expressing Cell Lines
(A and B) HEK293T cell lines were transfected with pMD2-
2A-VSVind.G, pMD2-2A-COCV.G, pMD2-2A-VSVnj.G,
and pMD2-2A-PIRYV.G. VesG-expressing HEK293T cells
were cultured under phleomycin selection starting at 48 hr
post-transfection. Throughout a 10-week period, these
stable envelope-expressing cells were analyzed for their (A)
envelope expression and (B) LV production by transient
transfection of gag-pol, rev, and vector expression plas-
mids. The data shown represent the mean titers ± SD for
the titrations performed in triplicate.
Molecular Therapy: Methods & Clinical Developmentsome time. To conﬁrm this, early-passage stable WinPac-COCV.G
producer cells were cultured in the presence of nevirapine, a non-
nucleoside inhibitor of HIV reverse transcriptase. These cells had a
lower LV genome number per cell than WinPac-COCV.G. Cells
cultured in the absence of nevirapine accumulated high copies of
the LV genome (Figure 7C).
A Mitigation to Superinfection: Cell-free in trans Pseudotyping
Genetic instability of vector producer cells caused by vector superin-
fection will be problematic in terms of product characterization. This
problem would apply to the construction of LV producer cell lines
with any of the VesGs we tested. However, stable expression of
each VesG in the absence of the LV genome was viable. We therefore
explored the possibility of admixing unenveloped LV particles with
VesG preparations because this has previously been reported to yield
infectious GRVs using VSVind.G.39 Figure 8A shows that this was
possible using transiently produced LV particles without an envelope
glycoprotein with transiently produced G protein preparations. Also,
infectious particles could be generated with stably produced unenvel-
oped LV particles and stably produced G protein preparations, with
titers up to 4.0  105 TUs/mL (Figure 8B), highlighting a production
process for LVs with VesGs that avoids transient plasmid transfec-
tion. By further optimization (e.g., use of clonal cells expressing a
high level of vector genome), vector titers over 106 TUs/mL should
be achievable. This system would increase titers and reproducibility
and remove the risk of plasmid DNA contamination of the LV
preparation.
DISCUSSION
Perhaps one of the most striking ﬁndings of this study is that
the VSVind.G protein is not demonstrably cytotoxic when stably306 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018expressed in cells. VSV is a lytic virus, but the
viral M protein is the major cause of cell death.40
However, an M mutant virus retains some cyto-
toxicity because of the G protein.41 The assump-
tion that VSVind.G alone cannot be stably
expressed seems to come from brief observations
reported by Burns et al. in 1993.4 Interestingly,
Humbert et al.42 also demonstrated recently that
stable expression of the VSVind.G and COCV.G
proteins is possible. However, they found lowerLV titers when VSVind.G-expressing cells were transfected with other
components,42 which we did not observe (Figure 3). Similarly to
Humbert et al.,42 we proceeded to develop packaging cells based on
COCV.G because it is resistant to complement inactivation (Fig-
ure 5A)17 and thermostable (Figure 4B). We also broadly mapped a
determinant on VSVind.G that was responsible for complement inac-
tivation (Figure 5), so chimeric envelopes or further deﬁned mutants
of VSVind.G, or indeed PIRYV.G, could also be used.
The construction of two COCV.G LV producer cell clones, for gfp and
a TCR-encoding LV, has been published previously.42 Here we report
the construction of a COCV.G gfp LV producer cell clone that could
generate 1.3 105 TUs/mL LV particles every harvest after scaling up
to a 560-mL Corning HYPERFlask (Figure 7). However, we believe
that vector superinfection, which is not addressed by Humbert
et al.,42 may constitute a problem for clinical LV production from
COCV.G producer cells. First, the extent of cell expansion we or
Humbert et al.42 report is insufﬁcient for clinical LV vector character-
ization and ﬁnal production. It is possible that vector superinfection
will prevent sufﬁcient cell expansion. Second, the COCV.G producer
cells will genetically change over time, making quality testing difﬁcult.
Finally, when using non-self-inactivating transfer vectors,8 the inﬁ-
delity of HIV reverse transcriptase (approximately 1 substitution
per 10,000 bases43) will lead to accumulation of defective vector ge-
nomes within the producer cells. These will reduce the titer of the
clinical LV and could generate mutant transgenes with potentially
deleterious clinical effects.
Thus, the challenge in the generation of stable vesiculovirus envelope
LV producer cell clones suitable for clinical use becomes that of inhib-
iting LV superinfection rather than that of envelope toxicity. One
Figure 4. All Envelopes Demonstrated High Physical and Thermal Stability
(A) Vectors were concentrated by high-speed ultracentrifugation. The titers before
and after concentration indicate successful concentration of these vectors. For all
pseudotypes, the percentage of recovery was higher than 50%. The graph repre-
sents three repeats from two separate transient LV productions; error bars indicate
SEM. (B) pMD2-2A-VesG LVs were divided into 3 groups: three cycles of freeze-
thawing, incubation at 37C for 2 and 6 hr, and incubation at 4C for 24 and 48 hr.
The functional titers were then determined via flow cytometric analysis, and the
percentage of recovery was calculated. Data represent the mean of three repeats
performed in duplicates from two separate batches of transient LV productions.
www.moleculartherapy.orgoption is mixing unenveloped viral particles with G proteins pro-
duced from stably transfected cells. This avoids plasmid transfection,
which would reduce cost, increase ease of scale-up and reproduc-
ibility, and also remove the risk of plasmid DNA contamination in
the LV preparation.44 However, the production of two separate com-
ponents may add cost and variability. Superinfection in stable vesicu-
lovirus envelope LV producer cell clones could also be blocked in a
number of ways. First, as we have shown, this can be prevented by
expanding cells in an HIV inhibitor (Figure 7), which would have
to be efﬁciently removed from the clinical LV. Second, it could be
possible to block LV/receptor interactions in the producer cell
cultures with the soluble receptor, receptor-associated protein
(RAP), or antibodies, as described for the VSVind.G LDL family
receptors20 or the additional receptor Lgr4.45 Finally, it could also
be possible to generate vesiculovirus envelope LV producer cell clones
in cell lines resistant to either vesiculovirus entry or LV replication at
post-entry steps.46–48
MATERIALS AND METHODS
Cell Culture
HEK293T andWinPac cells were cultured in DMEM (Sigma-Aldrich,
St. Louis, MO) containing 2 mM L-glutamine (Gibco, Carlsbad, CA)Molecular Thesupplemented with 50 U/mL penicillin, 50 mg/mL streptomycin
(Gibco), and 10% fetal calf serum (FCS) (Sigma-Aldrich or Gibco)
at 37C and 5% CO2. When indicated, antibiotics were added to
the culture medium (antibiotics and their working concentration
are listed in Table S1). The stable cell lines derived fromWinPac cells
as well as HEK293Ts are listed in Table S2.
Phylogenetic Analysis of Vesiculovirus and Rabies Virus G
Proteins Based on Amino Acid Sequences
G proteins of the major vesiculoviruses (VSVind, UniProt: P03522;
COCV, UniProt: O56677; VSVnj, UniProt: P04882; PIRYV,
UniProt: Q85213; Maraba virus, UniProt: F8SPF4; VSV Alagoas
strain [VSVala], UniProt: B3FRL4; Chandipura virus, UniProt:
P13180; Carajas virus, UniProt: A0A0D3R1Y6; and Isfahan virus,
UniProt: Q5K2K4) as well as the G protein of the rabies virus
(UniProt: Q8JXF6) were included in the analysis. The amino acid
sequences were aligned using the ClustalOmega online multiple
sequence alignment tool (EMBL-EPI). The evolutionary analyses
were conducted in MEGA7.49 The evolutionary history was inferred
by using the maximum likelihood method based on the Jones-
Taylor-Thornton matrix-based model.50 The tree with the highest
likelihood is shown, with the bootstrap conﬁdence values (out of
100) indicated at the nodes. The tree is drawn to scale, with branch
lengths measured in the number of substitutions per site, depicted
in the linear scale.
pMD2-2A-VesG Construction and Generation of Stable
Envelope-Expressing Cells
To successfully co-express the different envelopes with the reporter
gene, we designed a vector in which the marker gene (Sh ble) and
the envelope were linked by a 2A self-cleaving peptide sequence
(LLNFDLLKLAGDVESNPGYP) and both controlled by the
cytomegalovirus (CMV) promoter. The 2A peptide ﬂanked in the
desired restriction sites was ordered from Genewiz (South Plainﬁeld,
NJ). This sequence was then sub-cloned into the pMD2 backbone,
originated from pMD2.COCV.G (a kind gift from Dr. Hans Peter-
Kiem42) using the restriction enzymes PmlI and EcoRI to generate
the pMD2.2A plasmid. Following this, the phleomycin resistance
gene and VSVind.G, COCV.G, VSVnj.G, and PIRYV.G proteins
(codon-optimized G protein sequences for VSVnj.G and PIRYV.G
were purchased from Genewiz) were introduced by PmlI/XhoI and
XbaI/EcoRI sites, respectively. To generate stable envelope-expressing
cell lines, 3  106 HEK293T cells were transfected with 3 mg of the
respective pMD2.2A.VesG plasmid using FuGene6 and put under
phleomycin selection 48 hr later. The envelope expression levels of
the cell lines, as well as their transient LV titers were monitored
weekly.
Colony Formation
3 106 HEK293T cells were seeded in 10-cm plates. 24 hr thereafter,
they were transfected with VesG expression plasmids and pRDpro-
LF.8 48 hr post-transfection, cells were counted and seeded in three
different dilutions of 2.5  104, 5  103, and 103 cells/well in 6-well
plates. After a week of phleomycin selection, the medium wasrapy: Methods & Clinical Development Vol. 10 September 2018 307
Figure 5. LVs Bearing COCV.G and PIRYV.G Envelope Are Resistant to Inactivation by Complement
Vectors were diluted 1:20 (v/v) with serum-free medium or heat-inactivated (HI) or fresh human and mammalian serum, incubated at 37C for 1 hr, and then plated on
HEK293T cells. The percentage of GFP-positive cells was measured 2 days later via flow cytometry. Measured titers were normalized to those of serum-free samples. (A) The
reduction of titers by sera after heat-inactivation at 56C for 1 hr was less than 30% for all LVs. (B) Substantial proportions of LVs with VSVind.G, but not COCV.G, PIRYV.G, or
RDpro env, were inactivated by complement. The data shown represent relative titers ± SD for four experiments performed in duplicate. (C) The design and the cross-over
points of the chimeric G proteins are represented in linear diagrams, in which white bars stand for wild-type (WT) VSVind.G sequences, and WT COCV.G sequences are
represented by black hatched bars. The cross-over point between the two WT sequences is indicated by the amino acid number above the bar. (D) Sensitivity of LVs
pseudotyped with chimeric G proteins to inactivation by several mammalian sera. Reductions of titers by HI sera were less than 30% for all LVs (data not shown). The data
shown represent relative titers ± SD for four experiments performed in duplicate.
Molecular Therapy: Methods & Clinical Developmentremoved, and cells were washed with PBS and ﬁxed with absolute
methanol for 5 min. Wells were air-dried, and the cells were stained
with Giemsa (Sigma-Aldrich) for 30 min, washed with water, and
imaged using bright-ﬁeld microscopy (Hitachi, Tokyo, Japan).
Extracellular Antibody Binding Assay
G protein-expressing HEK293T and WinPac-COCV.G cells were
harvested, washed twice with PBS, and plated in U-bottom
96-well plates at identical densities. Cells were then incubated
with 1:500 or 1:200 dilutions of 8G5F11 (Kerafast, Boston, MA)
or VSV-Poly,26 respectively, in 1% BSA (Sigma-Aldrich) in PBS in
a total reaction volume of 200 mL for 30 min at 4C. After washing
twice with PBS (Sigma-Aldrich) to remove any unbound antibodies,
the cells were incubated for another 30 min at 4C with a 1:500
dilution of their respective ﬂuorophore-conjugated secondary anti-
bodies (the list of antibodies utilized is shown in Table S4) in
1% BSA in PBS in a total reaction volume of 200 mL. Cells were
then washed twice, ﬁxed in 2% paraformaldehyde (PFA), and
analyzed by ﬂow cytometry.308 Molecular Therapy: Methods & Clinical Development Vol. 10 SepteTransient LV Production
Three-plasmid co-transfection into HEK293T cells was used to make
pseudotyped LVs as described previously.3 Brieﬂy, 4  106 293FT
cells were seeded in 10-cm plates. 24 hr later, they were transfected
using FuGene6 (Promega, Madison, WI) with the following plasmids:
self-inactivating (SIN) pHV (a gfp expressing vector plasmid), p8.91
(a Gag-Pol-Rev expression plasmid3), and envelope expression plas-
mids (the details of these plasmids are listed in the Table S3). The me-
dium was changed after 24 hr, and then vector-containing medium
(VCM) was collected over 24-hr periods for 2 days. Following collec-
tion, VCM was passed through a 0.45-mm cellulose acetate ﬁlter and
either concentrated or directly stored at 80C.
LV Titration, Envelope Stability, and Infection Assays
The functional titer of each vector preparation was determined by
ﬂow cytometric analysis for GFP expression following transduction
of HEK293T cells. Brieﬂy, 2  105 293T cells were infected with
LVs plus 8 mg/mL Polybrene (Merck Millipore, Billerica, MA) for
24 hr. Infected cells were detected by EGFP expression usingmber 2018
Figure 6. Construction of the WinPac-COCV.G Producer Cell Line
(A) Schematic representation of pSIN-GFP-BSR (promoterless blasticidin vector
genome). (B) Total transduction units of COCV.G- and RDpro-enveloped LVs har-
vested from stable producers in Corning HYPERFlask 2D culture. 560 mL of LV-
containing medium was collected every 24 hr over 5 days. The data presented
represent the mean yield from a single large-scale production. Average titers of
COCV.G-LV and RDpro-LV harvested were 8.2  104 and 2.9  105 transduction
units (TUs)/mL, respectively. Titrations to determine the functional titers were per-
formed in triplicate. Data were obtained from cells 25–30 passages following anti-
biotic selection.
www.moleculartherapy.orgFACSCanto II (BD Biosciences, San Jose, CA) and Flowjo software
48 hr following the start of transduction. Titers were calculated
from virus dilutions, where 1%–20% of the cell population was
EGFP-positive, using the following formula:Titer

transduction units ðTUÞ
mL

=
ðno: of cells at transductionÞ  ð% of GFP  positive cells O100Þ  ðdilution factorÞ
ðthe volume of virus preparation added ðmLÞÞ :Infection assays for superinfection detection and envelope stability
were carried out similarly. For envelope stability, vectors were
titrated on HEK293T cells after either incubation at different
temperatures or freeze-thawing cycles. The percentage of recovery
was calculated according to the volume, and titers of the recov-
ered LVs were compared with the volume and titers of the
crude ones. On the other hand, to detect superinfection, stable
envelope-expressing cells, WinPac-RDpro, or WinPac-COCV.G
cells were challenged with VesG-pseudotyped LVs at MOI 0.5
or 3.0.
LV Concentration
Harvested VCM was concentrated 100-fold by ultra-centrifuga-
tion at 22,000 rpm (87,119  g) for 2 hr at 4C in a Beckmann
Optima LK-90 ultracentrifuge using the SW-28 swinging bucket
rotor (radius, 16.1 cm). The virus was resuspended in cold plain
OptiMEM on ice and incubated on ice for 1 hr before aliquoting
and storage at 80C.Molecular TheSerum Sensitivity Assay
Approximately 3 hr prior to infection, HEK293T cells were seeded
in 12-well plates at a density of 2  105 cells/well in 2 mL of
complete medium containing 8 mg/mL Polybrene (Merck Milli-
pore). Later, 2.5 mL of VesG-LV at a 1.6  107 TUs/mL titer
were mixed with plain OptiMEM (Gibco) and heat-inactivated
mammalian sera (human [catalog number S1764], guinea pig
[catalog number S1639], and rabbit [catalog number S7764] from
Sigma-Aldrich and mouse [catalog number IMS-C57BL6-COMPL]
from Patricell, Nottingham, UK) by incubation at 56C for
1 hr and fresh mammalian sera (1:20 v/v), incubated at 37C for
1 hr, and plated on the cells. 48 hr later, cells were harvested
and analyzed via ﬂow cytometry for EGFP expression. Relative
infection rates for all samples were normalized to that of
OptiMEM samples within individual VesG-LV using the following
equation:
Infection%=
titer of serum mixed sample
titer of OptiMEM mixed sample
 100 :
LV Production from Producer Cells
Cells were seeded at a density of 2.1–2.3  105 cells/cm2. After
72 hr, cells were washed with medium, and 0.08–0.1 mL/cm2 of
medium was replaced. 24 hr later, VCM was collected, passed
through a 0.45-mm cellulose acetate ﬁlter (SLS, Nottingham, UK),
and stored at 80C. Fresh medium was added to the cells for
collection after 24 hr. This process was repeated up to three times.
For HYPERFlask production, cells were expanded under antibioticselection and 10 mM nevirapine in the case of WinPac-COCV.G
and seeded at a density of 1.16  105 cells/cm2. 24 hr later,
VCM was collected, passed through a 0.45-mm cellulose acetate ﬁl-
ter, and stored at 80C.
qPCR for Time-Dependent Superinfection Study
To determine infection copies in WinPac-COCV.G cultured in the
presence and absence of 10 mM nevirapine, SYBR Green-based
qPCR was used. Initially, genomic DNA (gDNA) was extracted
from 2  106 cells using the DNeasy Blood and Tissue Kit
(QIAGEN, Crawley, UK) following the manufacturer’s instructions.
gDNA concentration was determined by spectrophotometry and
adjusted to 50 ng/mL. 100 ng of gDNA was used as a template
for qPCR reactions using the QuantiTect SYBR Green PCR Kit
(QIAGEN) and ABI 7500 real-time PCR system (Applied Bio-
systems, Warrington, UK). PCR reactions were performed at 95C
for 15 min, followed by 40 cycles of 95C for 15 s, 55C for 30 s,
and 72C for 30 s. A melting curve was run following each assay.rapy: Methods & Clinical Development Vol. 10 September 2018 309
Figure 7. Vector Copy Accumulation in WinPac-COCV.G Vector Producers because of Superinfection
(A) Superinfection is blocked in a WinPac-RDpro cell clone when challenged with RDpro-bearing LVs because of receptor interference (30, solid arrow), whereas there is a
lack of superinfection inhibition in WinPac-COCV.G cells (H4, dashed arrow). (B) Bulk populations of HEK293T cells stably expressing VesG and RDpro were challenged with
LVs pseudotyped with these G proteins at MOI 0.5. Although RDpro-expressing cells blocked RDpro-LV entry, others were permissive to infection by all LVs. The data
presented represent mean ± SEM of two experiments performed in duplicate. (C) qPCR quantification of superinfection in WinPac-COCV.G cultured with and without
nevirapine over 13 weeks. Infection was quantified by amplification of the integrated LV genome via qPCR and normalized to HB-actin copy numbers per cell. The data
presented represent mean ± SEM of the qPCR assay performed in triplicate. The map of the LV vector with the primer locations, the expected fragments before and after
integration, and the overall vector titers measured are shown in Figure S3.
Molecular Therapy: Methods & Clinical DevelopmentAll qPCR reactions were performed in triplicate. Infection was
quantiﬁed by ampliﬁcation of the LV genome via qPCR and
normalized to human beta (HB)-actin copy numbers per cell. The
data presented represent mean ± SEM of the qPCR assay performed
in triplicate. The standards and primers used, the map of the LV
vector with the primer locations, and the expected fragments before
and after integration are shown in Figure S4.
To calculate the DNA copy number per cell, b-actin was quantiﬁed in
parallel to any gene of interest and divided by 6 to give the number of
cells per reaction. This was done assuming HEK293T cells are triploid
and that the primer pair used (HB-actin-F and HB-actin-RC) detect
the b-actin gene (on chromosome 7) and b-actin pseudogene (on
chromosome 11).
The standards used in all qPCRs were 105, 104, 103, 102, and 101 plas-
mids/reaction. For b-actin and superinfection copies, the standards
were made by cloning the PCR product from HB-actin-F and RC
or 3LTR_fw_INFCross_Cp and 5LTR_INFCross_Cp, respectively,
into pJet (Thermo Fisher Scientiﬁc).310 Molecular Therapy: Methods & Clinical Development Vol. 10 SepteCell-free in trans Pseudotyping
Bald, unenveloped LV and soluble G proteins were produced either
transiently or stably. For transient production, HEK293T cells were
co-transfected with p8.91 and SIN pHV-GFP or VesG expression
plasmids using FuGene6.
Supernatant from cells expressing VesG proteins constitutively and
transiently were harvested 24 hr after cells were taken off of antibiotic
selection or 48 hr after transfection, respectively. In a similar fashion,
unenveloped GFP-encoding LVs were harvested from the bald
WinPac-GFP packaging cell line or HEK293T cells transiently trans-
fected. Bald LVs and soluble exogenous G proteins were mixed at a
1:3 v/v ratio, incubated at 37C for 1 hr, and plated ontoHEK293T cells.
The percentages of GFP-positive cells were measured 48 hr thereafter
via ﬂow cytometry, and titers were calculated as described previously.
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Figure 8. Infectious LV Formation by Admixing Unenveloped LV with
Exogenous G
(A) Non-infectious unenveloped LVs encoding GFP were mixed with supernatant
collected from cells transiently expressing vesiculovirus G proteins (VSVind, COCV,
and PIRYV) at a 1:3 v/v ratio, incubated at 37C for 1 hr, and plated onto HEK293T
cells. Percentages of GFP-positive cells were measured 48 hr thereafter via flow
cytometry. Cell supernatant COCV.G and PIRYV.G, albeit slightly less efficiently
than VSVind.G, made env-less LV infectious. (B) The same could be achieved using
supernatant collected fromWinPac-GFP and stable envelope-expressing cells. The
titers achieved by admixing were comparable or better than LVs produced via
transient transfection of envelope expression plasmids into the bulk WinPac-GFP
cell population. The data shown represent mean titers ± SD for three experiments
performed in duplicate.
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